| Revision as of 16:41, 29 December 2008 editZefryl (talk | contribs)148 edits multiple changes, see talk page← Previous edit | Revision as of 03:30, 30 December 2008 edit undoArcadian (talk | contribs)163,050 edits redir, per talkNext edit → | ||
| Line 1: | Line 1: | ||
| #REDIRECT ] | |||
| '''Noradrenergic and specific serotonergic antidepressants''' (abbreviated: '''NaSSAs''') are a relatively new class of ]s.<ref>{{cite journal |author=Kent J |title=SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression |journal=Lancet |volume=355 |issue=9207 |pages=911–8 |year=2000 |pmid=10752718 |doi=10.1016/S0140-6736(99)11381-3}}</ref> They are thought to work by blocking presynaptic ] that normally inhibit the release of the ]s ] (]) and ]. By releasing them from inhibitory control, NaSSAs act as ] for these neurotransmitters. NaSSAs are said to be ''specific'' serotonergic antidepressants since they have affinity for only certain serotonin receptors. ], for instance, has high affinity for the ] and ]s, but no significant affinity for the ] or ]s. | |||
| Examples of NaSSAs include: | |||
| * ] (Remeron, Zispin, Avanza, Norset, Remergil, Axit) | |||
| NaSSAs are said to have fewer side effects than ]s and ]s (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with Mirtazapine.<ref>{{cite journal |author=Fawcett J, Barkin R |title=Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression |journal=J Affect Disord |volume=51 |issue=3 |pages=267–85 |year=1998 |pmid=10333982 |doi=10.1016/S0165-0327(98)00224-9}} </ref> | |||
| ==See also== | |||
| * ] | |||
| ==References== | |||
| <references/> | |||
| {{Antidepressants}} | |||
| ] | |||
| {{treatment-stub}} | |||
| ] | |||
| ] | |||
Revision as of 03:30, 30 December 2008
Redirect to: